Background While there is evidence that COVID-19 vaccination protects against development of post-COVID conditions (PCC) after severe infection data are limited on whether vaccination reduces the risk after cases of less-severe non-hospitalized COVID-19 disease with more recent SARS-CoV-2 variant viruses. This study assessed whether COVID-19 vaccination was protective against subsequent development of PCC in persons with predominantly mild initial infections during both Delta and Omicron variant predominance. Methods This study utilized a case-control design, nested within the HEROES-RECOVER cohort. Participants aged ≥18 years with PCR-confirmed SARS-CoV-2 infection between 6/28/2021 and 9/14/2022 were surveyed for PCC, defined by symptoms lasting >1 month after initial infection Cases were participants self-reporting PCC and controls were participants that did not self-report PCC. The exposure was mRNA COVID-19 vaccination (2 or 3 monovalent doses) versus no COVID-19 vaccination. Logistic regression was used to compare the odds of PCC among vaccinated and unvaccinated persons; additional analyses evaluating PCC subtypes were also performed. Results A total of 936 participants with documented SARS-CoV-2 infection were included; of these 23.6% (221) reported PCC and 83.3% (779) were vaccinated. Participants who received a 3rd COVID-19 monovalent mRNA dose prior to infection had lower odds of PCC-related gastrointestinal, neurological, and other symptoms compared to unvaccinated participants (aOR: 0.37; 95% CI: 0.16-0.85; aOR: 0.56; 95% CI: 0.32-0.97; aOR:0.48; 95% CI: 0.25-0.91). Conclusions COVID-19 vaccination protected against development of PCC among persons with mild infection during both Delta and Omicron variant predominance, supporting vaccination as an important tool for PCC prevention.

中文翻译：

---

在美国前瞻性基本工作者队列中，mRNA COVID-19 疫苗接种与 SARS-CoV-2 感染后 COVID 后病情减少的关联


背景 虽然有证据表明 COVID-19 疫苗接种可以防止严重感染后 COVID 后疾病 （PCC） 的发展，但关于疫苗接种是否能降低较轻的非住院 COVID-19 疾病与最近的 SARS-CoV-2 变体病毒病例发生的风险的数据有限。本研究评估了在 Delta 和 Omicron 变体占主导地位期间，COVID-19 疫苗接种是否能防止主要为轻度初始感染的人随后发生 PCC。方法 本研究采用病例对照设计，嵌套在 HEROES-RECOVER 队列中。在 2021 年 6 月 28 日至 2022 年 9 月 14 日期间，年龄≥ 18 岁且经 PCR 确认感染 SARS-CoV-2 的参与者接受了 PCC 调查，其定义为症状在初始感染后持续 >1 个月病例是参与者自我报告 PCC，对照组是未自我报告 PCC 的参与者。暴露是 mRNA COVID-19 疫苗接种（2 或 3 剂单价剂量）与不接种 COVID-19 疫苗。采用 Logistic 回归比较接种疫苗和未接种疫苗者 PCC 的几率;还进行了评估 PCC 亚型的额外分析。结果 共纳入 936 名有 SARS-CoV-2 感染记录的参与者;其中 23.6% （221） 报告了 PCC，83.3% （779） 接种了疫苗。与未接种疫苗的参与者相比，在感染前接受第 3 剂 COVID-19 单价 mRNA 的参与者出现 PCC 相关胃肠道、神经和其他症状的几率较低（aOR：0.37;95% CI：0.16-0.85;aOR：0.56;95% CI：0.32-0.97;aOR：0.48;95% CI：0.25-0.91）。 结论 在 Delta 和 Omicron 变体占主导地位期间，COVID-19 疫苗接种可防止轻度感染者发生 PCC，支持疫苗接种作为预防 PCC 的重要工具。